论文信息 - SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Sandra Mossuto, Enrico Attardi, Francesco Alesiani, Emanuele Angelucci, Enrico Balleari, Massimo Bernardi, Gianni Binotto, Costanza Bosi, Anna Calvisi, Isabella Capodanno, Antonella Carbone, Andrea Castelli, Marco Cerrano, Rosanna Ciancia, Daniela Cilloni, Marino Clavio, Cristina Clissa, Elena Crisà, Monica Crugnola, Matteo G. Della Porta, Nicola Di Renzo, Ambra Di Veroli, Roberto Fattizzo, Carmen Fava, Susanna Fenu, Ida L. Ferrara, Luana Fianchi, Carla Filì, Carlo Finelli, Valentina Giai, Francesco Frattini, Valentina Gaidano, Gianluca Guaragna, Svitlana Gumenyuk, Roberto Latagliata, Stefano Mancini, Emanuela Messa, Alfredo Molteni, Pellegrino Musto, Pasquale Niscola, Esther Oliva, Giuseppe A. Palumbo, Annamaria Pelizzari, Federica Pilo, Antonella Poloni, Marta Riva, Flavia Rivellini, Chiara Sarlo, Mariarita Sciumé, Roberto Secchi, Carmine Selleri, Agostino Tafuri, Valeria Santini

[1] G. Corrao,et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study , 2020, The Lancet Haematology.

[2] G. Remuzzi,et al. Adaptations and Lessons in the Province of Bergamo , 2020, The New England journal of medicine.

[3] M. Cappellini,et al. SARS‐CoV‐2 infection in beta thalassemia: Preliminary data from the Italian experience , 2020, American journal of hematology.

[4] R. Foà,et al. Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment , 2019, Hematological oncology.

[5] M. Rudelius,et al. Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients , 2019, Blood Cancer Journal.

[6] M. Voso,et al. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. , 2019, Blood reviews.

[7] U. Germing,et al. Causes of death in 2877 patients with myelodysplastic syndromes , 2016, Annals of Hematology.

[8] H. Kantarjian,et al. Cause of death in patients with lower‐risk myelodysplastic syndrome , 2010, Cancer.